Astellas FY26 Net Profit Nearly Quintuples to ¥292 Billion as Operating Profit Recovers 832% from Impairment-Plagued Base; Annual Dividend Lifted to ¥78

Astellas Pharma Inc. (TSE: 4503), Japan's second-largest pharmaceutical company by revenue and a global specialty-pharma player focused on oncology, ophthalmology and immunology, reported FY3/2026 consolidated IFRS results showing a dramatic earnings rebound driven by the non-recurrence of prior-year impairments combined with healthy top-line growth from key franchise products. Revenue rose 11.9% to ¥2,139.2 billion, operating profit surged 832.4% to ¥382.6 billion, profit before tax recovered to ¥376.6 billion (vs ¥41.0 billion prior — a 9-fold increase), profit attributable to owners climbed 474.5% to ¥291.5 billion, and comprehensive income soared 819.4% to ¥449.5 billion. Basic EPS came in at ¥162.77 (vs ¥28.35 prior).

The base effect: ¥244 billion of FY25 impairments do not repeat

The eye-popping growth percentages require careful framing. FY3/2025's reported earnings were depressed by approximately ¥244 billion of intangible-asset impairments tied to prior M&A — most prominently the Iveric Bio (geographic-atrophy assets, acquired 2023 for $5.9 billion) franchise, where commercial uptake of IZERVAY was slower than the deal's original modeling assumed, and the Veloxis transplant franchise. With those impairments fully reflected in the FY25 base, FY3/2026 returned to a "clean" earnings profile, producing the optical 832% / 475% recovery in operating profit and net profit. Underlying business growth — top-line +11.9% — is the real signal here, not the +832% OP optic. Operating margin nonetheless expanded to a healthy 17.9% from 2.1%.

Padcev, Xtandi, Vyloy and IZERVAY — the four-engine portfolio

The growth profile is anchored by four products: Padcev (enfortumab vedotin) for advanced urothelial cancer (in combination with Keytruda) continues to take share in the 1L bladder cancer setting; Xtandi (enzalutamide) remains the standard-of-care for non-metastatic CRPC despite increasing generic-erosion pressure in earlier-line use; Vyloy (zolbetuximab) for HER2-negative, claudin-18.2-positive gastric cancer — launched in late 2024 — is the company's most strategic new launch, addressing a meaningful unmet need and beginning to inflect commercially in this period; and IZERVAY (avacincaptad pegol) for geographic atrophy of the retina, where uptake has been more measured but recovering. Mature products (Lexiscan, Mycamine, Prograf) and Veloxis transplant business remained relatively stable.

Balance sheet expands; cash flow inflects

Total assets grew to ¥3,567.0 billion from ¥3,339.5 billion, total equity climbed to ¥1,830.9 billion from ¥1,513.3 billion, and parent owners' equity rose to ¥1,829.0 billion. The owners' equity ratio strengthened to 51.3% from 45.3%. BPS reached ¥1,020.96 (post-split-adjusted basis) from ¥845.25. Operating cash flow nearly tripled to ¥560.2 billion from ¥194.5 billion as earnings normalized and working capital improved. Investing outflow stayed disciplined at ¥66.7 billion; financing outflow widened to ¥404.8 billion on dividend payments, buybacks and debt repayment. Cash and equivalents finished at ¥281.6 billion.

Dividend lifted to ¥78; FY27 guides ¥80

The annual dividend was set at ¥78 per share (¥39 interim + ¥39 year-end), up from ¥74 in the prior year (¥37 + ¥37). The payout ratio normalized to 47.9% from the extraordinary 261.1% seen in FY25 (when the impairment-depressed earnings made the dividend look disproportionately high). For FY3/2027, management guides the dividend further up to ¥80 per share (¥40 + ¥40), implying continued capital-return commitment alongside the underlying business recovery.

Outlook: continued late-stage pipeline execution

The detailed FY3/2027 P&L guidance accompanies this disclosure (specific guidance figures are presented in the full report; major analysts expect Astellas to guide for revenue growth of around 5–8% with continued OP-margin expansion as the impairment-comparable normalization completes). The strategic focus areas remain: (i) continuing the Vyloy launch and IZERVAY commercial recovery; (ii) advancing the next-wave oncology pipeline (PD-1xLAG-3 bispecifics, ASLAN, novel ADC platforms); (iii) disciplined M&A — Astellas has signaled the post-Iveric era will favor smaller, lower-risk bolt-ons. No going-concern issues or material subsequent events noted.

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.